Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and Shire Viropharma (NASDAQ:VPHM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

This table compares Adamis Pharmaceuticals Corporation and Shire Viropharma’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Adamis Pharmaceuticals Corporation $11.39 million 13.21 -$18.97 million N/A N/A
Shire Viropharma N/A N/A N/A N/A N/A

Shire Viropharma has higher revenue, but lower earnings than Adamis Pharmaceuticals Corporation.

Institutional and Insider Ownership

10.1% of Adamis Pharmaceuticals Corporation shares are held by institutional investors. 9.6% of Adamis Pharmaceuticals Corporation shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Adamis Pharmaceuticals Corporation and Shire Viropharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals Corporation -158.51% -69.03% -47.51%
Shire Viropharma N/A N/A N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Adamis Pharmaceuticals Corporation and Shire Viropharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals Corporation 0 0 3 0 3.00
Shire Viropharma 0 0 0 0 N/A

Adamis Pharmaceuticals Corporation presently has a consensus price target of $9.83, indicating a potential upside of 104.86%. Given Adamis Pharmaceuticals Corporation’s higher possible upside, equities analysts clearly believe Adamis Pharmaceuticals Corporation is more favorable than Shire Viropharma.

Summary

Adamis Pharmaceuticals Corporation beats Shire Viropharma on 5 of the 8 factors compared between the two stocks.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

About Shire Viropharma

ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich’s Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich’s Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.